AI drug discovery claims and their evidence chain
An audit traces phase 2 AI-drug claims to their sources, distinguishing small outcome samples, interim pipeline counts, completion from success, and arguments about bottlenecks.
I use Google Analytics to understand site visits. Allow optional analytics cookies? Privacy
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
ORCIDGoogle ScholarLinkedInGitHub
An audit traces phase 2 AI-drug claims to their sources, distinguishing small outcome samples, interim pipeline counts, completion from success, and arguments about bottlenecks.
Testing a one-parameter model on held-out HER2-positive mixture fractions and separated tumoroids reveals limits of a fraction-only explanation.
FDA taletrectinib models compare food and dose conditions, distinguishing lower exposure, relative hepatic-toxicity hazards, and unverified regular-meal effects.